Biotech News 4 October 2025

Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

RANI Stock Price Explodes on Deal News Rani Therapeutics’ stock price skyrocketed on Friday, Oct. 17, after the company unveiled a major partnership and funding news. In pre-market trade, RANI jumped about 150% and continued to rally after the market

17 October 2025

Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp?

Stock Price Rollercoaster in 2025 Adaptimmune’s stock has been on a wild ride this year, with extreme price swings in recent weeks grabbing headlines. After languishing in penny-stock territory for months, ADAP suddenly caught fire in late September 2025. On

16 October 2025

Biotech · Company Analysis · Investing · NASDAQ:ADAP · NASDAQ:HTGC · Pharmaceuticals · Stock Market

Biotech Meets Crypto: ENDRA Life Sciences (NDRA) Stock Skyrockets 33% — Analyst Target $50

Stock Performance Over the past few trading days, NDRA moved sharply higher. It closed $6.48 on Oct 10, 2025 stockinvest.us, up modestly from ~$5.75 a week earlier. On Oct. 13, after the morning press release, the stock leapt 33.1% to

13 October 2025

Biotech · Cryptocurrency · Investment · Market Analysis · NASDAQ:NDRA · Stocks

AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

Stock Performance & Recent Trends AbbVie’s stock closed at $230.88 on Oct. 10, 2025 marketbeat.com. Over the prior five trading days it moved modestly: Oct. 7: $232.83; Oct. 8: $231.24; Oct. 9: $230.69; Oct. 10: $230.50 investing.com. Notably, on Sept. 30 ABBV hit a 52-week

11 October 2025

Biotech · Financial Analysis · Investing · NYSE:ABBV · Pharmaceuticals · Stock Market

Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Company Overview Protagonist Therapeutics is a clinical-stage biopharma company leveraging peptide technology to create new medicines for rare hematologic conditions and prevalent immunological diseases protagonist-inc.com. Founded in 2008, Protagonist has built its identity around engineered peptide drugs – a niche

11 October 2025

Biotech · Clinical Trials · Mergers & Acquisitions · Pharmaceuticals · Stock Market

Bristol Myers Snaps Up Orbital Therapeutics in $1.5B Biotech Power Play

In-Depth Analysis BMS’s acquisition of Orbital Therapeutics marks a deliberate push into autoimmune disease treatment via advanced cell therapy. Orbital, founded in 2022 by leaders in RNA and immunology, has built a proprietary RNA platform combining circular and linear RNA

10 October 2025

Biotech · Healthcare Industry · Investment · Mergers & Acquisitions · NYSE:BMY · Pharma News

Turn Therapeutics (TTRX) Skyrockets After Nasdaq Debut – Biotech Breakthrough or Hype?

Company Profile – Background & Leadership Turn Therapeutics, Inc. is a Westlake Village, CA-based biotech company founded in 2015 renaissancecapital.com. The company (formerly named Global Health Solutions, Inc.) officially rebranded to Turn Therapeutics in Sept 2025 ahead of its Nasdaq listing stockanalysis.com. Turn’s

9 October 2025

Biotech · Healthcare Innovation · Investment Analysis · IPO · NASDAQ:TTRX · Stock Market

Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real?

Therapy (Target) Indication Status (2025) Current Ownership TECELRA(afamitresgene, targets MAGE-A4) Synovial sarcoma (unresectable/metastatic) FDA approved Aug 2024 biospace.com; ~16 patients treated in launch year nasdaq.com. Sold to US WorldMeds (2025) adaptimmune.com Letetresgene (lete-cel, NY-ESO-1) MRCLS and synovial sarcoma (advanced solid tumors) Phase

8 October 2025

Biotech · Company Analysis · Financial News · Investing · NASDAQ:ADAP · Stock Market

Dyne Therapeutics Skyrockets on Breakthrough Data – Inside the Surge, Financials & 2026 Catalysts

Recent Stock Performance & Surge on Data Dyne Therapeutics’ stock has been on a tear following its latest clinical breakthroughs. Shares jumped 10–11% intraday on October 7, 2025, after the company reported positive one-year results from a key trial, lifting

7 October 2025

Biotech · Clinical Trials · Investment · NASDAQ:DYN · Pharma News · Stock Market

Galecto Stock Skyrockets 600% – Short Squeeze Mania or Biotech Breakthrough?

GLTO’s 632% Stock Spike: What Just Happened? Galecto’s stock made headlines on October 7, 2025 by soaring roughly six-fold in value within hours. In pre-market trading that morning, GLTO was up about 632% at one point stocktwits.com stocktwits.com. Shares that had closed around

7 October 2025

Biotech · Financial News · Investing · NASDAQ:GLTO · Short Squeeze · Stock Market

Spruce Biosciences Skyrockets on FDA Breakthrough – Will SPRB’s Rally Last or Fade?

Stock Performance & Recent Price Action Spruce Biosciences’ stock has been on a wild ride in early October 2025. Heading into this period, SPRB was a little-known micro-cap biotech trading in the high single digits (post-reverse-split). At the close on

6 October 2025

Biotech · FDA Approvals · Health News · Investing · NASDAQ:SPRB · Stock Market

Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Cidara Therapeutics (NASDAQ: CDTX) 2025 Investment Analysis – Will This Anti‑Flu Innovator Keep Soaring?

2025 Year‑to‑Date Stock Performance Cidara’s stock has been among the best performers in biotech. According to YTDReturn.com, a US$10,000 investment on 31 Dec 2024 would have grown to ~US$37,943 by 3 Oct 2025 because the share price increased from US$26.88 to US$101.99, a 279.43 %

4 October 2025

Biotech · Investment Analysis · Market Trends · NASDAQ:CDTX · Pharmaceuticals · Stock Market · Stocks

Biotech News 4 October 2025 - 17 October 2025